Head-To-Head Survey: GH Research (NASDAQ:GHRS) vs. Anthera Pharmaceuticals (OTCMKTS:ANTH)

Anthera Pharmaceuticals (OTCMKTS:ANTH) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Anthera Pharmaceuticals and GH Research, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthera Pharmaceuticals	0	0	0	0	0.00
GH Research	1	1	7	0	2.67

GH Research has a consensus target price of $30.00, suggesting a potential upside of 106.04%. Given GH Research’s stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than Anthera Pharmaceuticals.

Earnings and Valuation

This table compares Anthera Pharmaceuticals and GH Research”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GH Research	N/A	N/A	-$38.96 million	($0.74)	-19.68

Institutional and Insider Ownership

56.9% of GH Research shares are held by institutional investors. 2.1% of Anthera Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Anthera Pharmaceuticals and GH Research’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anthera Pharmaceuticals	N/A	N/A	N/A
GH Research	N/A	-15.84%	-15.27%

Volatility & Risk

Anthera Pharmaceuticals has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.